

Fragment-based drug discovery explained by leaders, Astex Pharmaceuticals

Advances and Progress in Drug Design, 16th & 17 February 2015, London UK

LONDON, LONDON, UNITED KINGDOM, November 6, 2014 /EINPresswire.com/ -- Astex Pharmaceuticals, a leader in fragment-based drug discovery, was acquired in October 2013 by Japanese firm Otsuka Pharmaceutical for about \$886m. The deal promised to enhance Astex's capacity to develop new therapeutics while Otsuka could tap into its potential new drugs.

Now over one year on, hear from Astex Pharmaceuticals as Director of Computational Chemistry, Gianni Chessari, addresses delegates at SMi's 14th annual conference next February in London, Advances & Progress in [Drug Design](#).



The talk entitled: Fragment Based Design of Protein-Protein Interaction Antagonists, will provide unique insights into:

“

high-level, well-organized event”

Research Centre for Natural Sciences, Hungary

- X-ray and biophysical fragment screening of protein-protein interaction targets
- Structure based driven optimisation of mM fragment into potent lead molecules
- Development of potent dual antagonist of XIAP and cIAP1

The Drug Design conference series has received positive feedback from the industry including previous speaker, Dr György Miklós Keserű, Director General from the Research Centre for Natural Sciences in Hungary

“It has a long tradition for SMi organizing Advances and Progress in Drug Design that is a high-level, well-organized event dedicated to actual challenges and potential solutions of rational drug design. Participants representing both big and mid-pharma companies, biotech organizations,

software providers as well as academia enjoy the informal atmosphere of the meeting that provides excellent networking opportunities.”

Further information is available online at www.drug-design.co.uk

Advances & Progress in Drug Design

16 – 17 February 2015

Marriott Regents Park Hotel, London UK

www.drug-design.co.uk

--- End ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.

We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at <http://www.smi-online.co.uk>

About Astex Pharmaceuticals:

Astex is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases. As part of Japan’s leading pharmaceutical company, Otsuka Pharmaceutical Co. Ltd., Astex operates from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Dublin, California, USA. <http://www.astx.com>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/233192224>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.